American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer
| Autor: | Andrea S. Wolf, Kristin Higgins, Arya Amini, Joe Chang, Benjamin Movsas, Igor I. Rybkin, Pranshu Mohindra, Charles B. Simone, Larry L. Kestin, George Rodrigues, Indrin J. Chetty, Stephen G. Chun, J. Isabelle Choi, Annemarie Shepherd, Jessica S. Donington, Kenneth E. Rosenzweig, Benjamin Slotman, Vivek Verma, Martin J. Edelman |
|---|---|
| Přispěvatelé: | Radiation Oncology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Cancer Research
medicine.medical_specialty Lung Neoplasms Radiation business.industry medicine.medical_treatment Radiosurgery medicine.disease SABR volatility model Systemic therapy Appropriate Use Criteria Targeted therapy Clinical trial Radiation therapy Systematic review Oncology Carcinoma Non-Small-Cell Lung medicine Humans Radiology Nuclear Medicine and imaging Lung cancer Intensive care medicine business Radium |
| Zdroj: | Expert Panel Thoracic Malignancies 2022, ' American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer ', International Journal of Radiation Oncology Biology Physics, vol. 112, no. 2, pp. 361-375 . https://doi.org/10.1016/j.ijrobp.2021.09.022 International Journal of Radiation Oncology Biology Physics, 112(2), 361-375. Elsevier Inc. |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2021.09.022 |
| Popis: | Purpose Recent randomized studies have suggested improvements in progression-free and overall survival with the addition of stereotactic body radiation therapy (SBRT, also known as SABR) in patients with oligometastatic non-small cell lung cancer. Given the novelty and complexity of incorporating SBRT in the oligometastatic setting, the multidisciplinary American Radium Society Lung Cancer Panel was assigned to create appropriate use criteria on SBRT as part of consolidative local therapy for patients with oligometastatic and oligoprogressive non-small cell lung cancer. Methods and Materials A review of the current literature was conducted from January 1, 2008, to December 25, 2020, using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines to systematically search the PubMed database to retrieve a comprehensive set of relevant articles. Results Based on representation in existing randomized trials, the panel defined the term “oligometastasis” as ≤3 metastatic deposits (not including the primary tumor) in the previously untreated setting or after first-line systemic therapy after the initial diagnosis. “Oligoprogression” also referred to ≤3 discrete areas of progression in the setting of prior or ongoing receipt of systemic therapy. In all appropriate patients, the panel strongly recommends enrollment in a clinical trial whenever available. For oligometastatic disease, administering first-line systemic therapy followed by consolidative radiation therapy (to all sites plus the primary/nodal disease) is preferred over up-front radiation therapy. Owing to a dearth of data, the panel recommended that consolidative radiation therapy be considered on a case-by-case basis for 4 to 5 sites of oligometastatic disease, driver mutation-positive oligometastatic disease without progression on up-front targeted therapy, and oligoprogressive cases. Conclusions Although SBRT/SABR appears to be both safe and effective in treating patients with limited metastatic sites of disease, many clinical circumstances require individualized management and strong multidisciplinary discussion on account of the limited existing data. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|